HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Article Details
- CitationCopy to clipboard
Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T
HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Toxicol Lett. 1997 Dec;93(2-3):215-9. doi: 10.1016/s0378-4274(97)00098-2.
- PubMed ID
- 9486958 [ View in PubMed]
- Abstract
The protease inhibitors, ritonavir, indinavir and saquinavir, the most potent anti-HIV drugs developed to date, interact with many drugs by competing for CYP3A4, an enzyme central to the metabolism of a wide variety of compounds. Human liver microsomes were used to compare inhibition by these three protease inhibitors. The inhibition was the greatest with ritonavir and indinavir and less potent with saquinavir.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Indinavir Cytochrome P450 3A4 Protein Humans UnknownSubstrateInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareColchicineIndinavir The serum concentration of Colchicine can be increased when it is combined with Indinavir. VoriconazoleAmprenavir The serum concentration of Voriconazole can be increased when it is combined with Amprenavir. VoriconazoleFosamprenavir The serum concentration of Voriconazole can be increased when it is combined with Fosamprenavir. VoriconazoleTipranavir The serum concentration of Voriconazole can be increased when it is combined with Tipranavir. VoriconazoleAsunaprevir The serum concentration of Voriconazole can be increased when it is combined with Asunaprevir.